What is Fosanis?
Founded in 2017, Fosanis GmbH operates at the intersection of oncology and digital health. The company is best known for developing Mika, an AI-powered digital therapeutic (DTx) platform designed to support cancer patients throughout their treatment journey. By leveraging electronic patient-reported outcomes (ePROs) and scientifically validated psycho-oncological interventions, Mika provides a personalized coaching experience that monitors symptoms and distress levels in real-time. The platform's status as a clinically proven DiGA, approved for all cancer patients, distinguishes it as a high-authority solution in a competitive healthtech market, effectively transforming how patients interact with their care teams and manage their disease progression.
How much funding has Fosanis raised?
Fosanis has raised a total of $10.6M across 1 funding round:
Series A
$10.6M
Series A (2022): $10.6M with participation from Ananda Impact Ventures, EquityPitcher, and Ship2B Ventures
Key Investors in Fosanis
Ananda Impact Ventures
Ananda Impact Ventures partners with visionary founders to invest in innovative technologies, focusing on critical challenges in healthcare and sustainability to drive impactful, long-term change.
EquityPitcher
EquityPitcher Ventures is a venture capital firm that invests in world-changing technologies, utilizing an extensive industry network to support B2B tech startups with high growth potential.
Ship2B Ventures
Ship2B Ventures focuses on impact startups that address significant social and environmental challenges, fostering systemic change through a community-driven approach to venture capital.
What's next for Fosanis?
With the recent influx of capital, Fosanis is poised to accelerate its strategic roadmap, focusing on the expansion of its clinical footprint and the enhancement of its AI-driven monitoring capabilities. The company is expected to prioritize the integration of its platform into international healthcare systems, leveraging its proven efficacy to drive adoption among oncological research institutions. Furthermore, the firm will likely invest in deepening its data analytics infrastructure to refine its personalized coaching algorithms, ensuring that Mika remains at the forefront of evidence-based digital medicine. As the company scales, its focus will remain on maintaining rigorous clinical standards while expanding its reach to address the unmet needs of cancer patients globally.
See full Fosanis company page
